Real-time Estimate
Cboe BZX
01:01:56 2024-06-10 pm EDT
|
5-day change
|
1st Jan Change
|
1.705
USD
|
-3.67%
|
|
+0.59%
|
-88.38%
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,448
|
993.9
|
120.4
|
-
|
-
|
Enterprise Value (EV)
1 |
2,101
|
622.5
|
32.99
|
57.87
|
-13.76
|
P/E ratio
|
-10.9
x
|
21
x
|
-0.66
x
|
-1.34
x
|
-1.71
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
110
x
|
2.61
x
|
1.28
x
|
-
|
933
x
|
EV / Revenue
|
94.5
x
|
1.63
x
|
0.35
x
|
-
|
-107
x
|
EV / EBITDA
|
-10.5
x
|
15.6
x
|
-0.17
x
|
-0.47
x
|
0.11
x
|
EV / FCF
|
-11.5
x
|
58.3
x
|
0.3
x
|
0.33
x
|
-0.06
x
|
FCF Yield
|
-8.68%
|
1.72%
|
339%
|
301%
|
-1,697%
|
Price to Book
|
-
|
2.26
x
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
66,256
|
67,518
|
68,006
|
-
|
-
|
Reference price
2 |
36.95
|
14.72
|
1.770
|
1.770
|
1.770
|
Announcement Date
|
3/13/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
0.285
|
22.23
|
380.8
|
94.3
|
-
|
0.129
|
EBITDA
1 |
-
|
-
|
-200.9
|
39.89
|
-192.8
|
-123.6
|
-128.7
|
EBIT
1 |
-
|
-82.69
|
-201.3
|
38.8
|
-201
|
-117.5
|
-98.1
|
Operating Margin
|
-
|
-29,013.33%
|
-905.72%
|
10.19%
|
-213.14%
|
-
|
-76,048.58%
|
Earnings before Tax (EBT)
1 |
-
|
-87.93
|
-
|
54.3
|
-269.4
|
-109.8
|
-55.3
|
Net income
1 |
-42.28
|
-87.93
|
-198.4
|
49.27
|
-159.2
|
-89.15
|
-73.9
|
Net margin
|
-
|
-30,852.98%
|
-892.38%
|
12.94%
|
-168.82%
|
-
|
-57,283.72%
|
EPS
2 |
-6.960
|
-13.35
|
-3.390
|
0.7000
|
-2.670
|
-1.318
|
-1.038
|
Free Cash Flow
1 |
-
|
-75.15
|
-182.4
|
10.68
|
111.8
|
174
|
233.4
|
FCF margin
|
-
|
-26,369.12%
|
-820.5%
|
2.8%
|
118.56%
|
-
|
180,930.23%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
26.77%
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
21.67%
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/26/21
|
3/30/22
|
3/13/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
0.345
|
21.88
|
71.43
|
98.22
|
102.7
|
108.4
|
88.64
|
8.53
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-52.28
|
-47.81
|
-54.25
|
-54.68
|
-44.59
|
-2.053
|
20.2
|
18.72
|
1.934
|
-11.67
|
-60.17
|
-49.31
|
-42.96
|
-35.35
|
Operating Margin
|
-
|
-
|
-
|
-15,849.57%
|
-203.76%
|
-2.87%
|
20.57%
|
18.23%
|
1.78%
|
-13.16%
|
-705.42%
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-54.24
|
-47.7
|
-
|
-
|
-
|
1.403
|
24.01
|
22.41
|
6.476
|
-118.6
|
-64.8
|
-47
|
-39
|
-
|
Net income
1 |
-54.24
|
-47.85
|
-54.07
|
-53.76
|
-42.7
|
1.573
|
22.07
|
20.89
|
4.731
|
-118.8
|
-38.7
|
-32.82
|
-28.5
|
-
|
Net margin
|
-
|
-
|
-
|
-15,581.45%
|
-195.13%
|
2.2%
|
22.47%
|
20.35%
|
4.36%
|
-134.01%
|
-453.68%
|
-
|
-
|
-
|
EPS
2 |
-4.150
|
-0.9300
|
-0.9300
|
-0.9200
|
-0.6500
|
0.0200
|
0.3100
|
0.3000
|
0.0700
|
-1.750
|
-0.6975
|
-0.5500
|
-0.4350
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/30/22
|
5/12/22
|
8/11/22
|
11/10/22
|
3/13/23
|
5/11/23
|
8/10/23
|
11/9/23
|
2/22/24
|
5/9/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
96.1
|
347
|
371
|
87.4
|
62.5
|
134
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-75.2
|
-182
|
10.7
|
112
|
174
|
233
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-209%
|
12.7%
|
-26%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
10.8%
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
454.5
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
6.520
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-
|
-
|
-3.070
|
0.1700
|
-0.5500
|
-1.690
|
-
|
Capex
1 |
-
|
0.35
|
2.53
|
1.24
|
1.3
|
2.9
|
3.34
|
Capex / Sales
|
-
|
123.86%
|
11.36%
|
0.33%
|
1.37%
|
-
|
2,586.82%
|
Announcement Date
|
4/26/21
|
3/30/22
|
3/13/23
|
2/22/24
|
-
|
-
|
-
|
Last Close Price
1.77
USD Average target price
4.083
USD Spread / Average Target +130.70% Consensus |
1st Jan change
|
Capi.
|
---|
| -88.38% | 120M | | +0.82% | 91.94B | | -3.16% | 38.74B | | +64.83% | 26.66B | | -12.53% | 15.32B | | -5.86% | 13.3B | | -11.38% | 11.65B | | +156.85% | 10.37B | | -49.84% | 10.12B | | +2.32% | 9.06B |
Biopharmaceuticals
|